ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Cheng, Binbin; Pan, Wei; Xing, Yi; Xiao, Yao; Chen, Jianjun*; Xu, Zheng*华南农业大学; 南方医科大学; 6
European Journal of Medicinal Chemistry2022-2-15DOI: 10.1016/j.ejmech.2022.114109
37被引6阅读
引用收藏
分享

摘要

DDR (DNA damage response) defects in cells drive tumor formation by promoting DNA mutations, which also provides cancer-specific vulnerabilities that can be targeted by synthetic lethality-based therapies. Until now, PARP inhibitors like olaparib are the first successful case of utilizing synthetic lethality-based therapy to treat cancers with DNA-repairing deficiency (e.g. BRCA1 or BRCA2 mutation), which has fueled the search for more targetable components in the DDR signaling pathway by exploiting synthetic lethality, including but not limited to DNA-PK, ATR, ATM, CHK1, and WEE1. After years of efforts, numerous DDR kinase inhibitors have been discovered. Some of them are being investigated in clinical trials and have shown promising results for cancer therapy. In this review, we summarize the latest advancement in the development of DDR kinase inhibitors including those in preclinical stages and clinical trials, the crystal structures of DDR enzymes, and binding modes of inhibitors with target proteins. The biological functions involving different genes and proteins (ATR, DNA-PK, ATM, PARP, CHK1, and WEE1) are also elucidated.

学科与关键词

关键词
DNA damage ResponseSynthetic lethalitySmall molecule inhibitors
相关
加载中…
  • Role of deubiquitinases in DNA damage response.
    Le John; Perez Eric; Nemzow Leah; Gong Feng*DNA Repair (Amst), 2019, 76: 89-98.
  • Structural insights into the critical DNA damage sensors DNA-PKcs, ATM and ATR
    Domagoj Baretic; Taiana Maia de Oliveira; Martina Niess; Paul Wan; Hannah Pollard; Christopher M Johnson; Caroline Truman; Eileen McCall; David Fisher; Roger Williams; Christopher PhillipsPROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2019.
  • The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
    Shi, Congqi; Qin, Kaiyu; Lin, Anqi; Jiang, Aimin; Cheng, Quan; Liu, Zaoqu; Zhang, Jian*; Luo, Peng*JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41(1): 268.被引 16
查看全部 →

发表信息

论文状态
公开发表
期刊
European Journal of Medicinal Chemistry
发表日期
2022-02-15
卷期
第 230 卷
页码
114109
DOI
10.1016/j.ejmech.2022.114109
语言
MULTI-LANGUAGE
期刊等级
1区
成果收录
SCIE
资助标注
Wuhan Municipal Health Com-mission of China [WX21Q48]; International Science and Technology Cooperation Projects of Guangdong Province of China [G819310411]; Foshan Outstanding Young Medical Talents Project grants, Foshan Medical Science and Technology [2020001004341]; scientific research project of high level talents in Southern Medical University [C1051008]

作者

  • C

    Cheng, Binbin (第一作者)

    polytech univ

  • P

    Pan, Wei

    6

查看全部 6 位作者收起作者
  • X

    Xing, Yi

    tianjin med univ

  • X

    Xiao, Yao

    wuhan univ sci & technol

  • C

    Chen, Jianjun (通讯)

    new · southern med univ

  • X

    Xu, Zheng (通讯)

    south china agr univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417